INCREASED LEVELS OF GLYCOSAMINOGLYCANS DURING SEPTIC SHOCK: RELATION TO MORTALITY AND THE ANTIBACTERIAL ACTIONS OF PLASMA

被引:251
作者
Nelson, Axel [1 ]
Berkestedt, Ingrid [1 ]
Schmidtchen, Artur [2 ]
Ljunggren, Lennart [3 ]
Bodelsson, Mikael [1 ]
机构
[1] Lund Univ, Dept Clin Sci, Sect Anesthesiol & Intens Care, Lund, Sweden
[2] Lund Univ, Dept Clin Sci, Sect Dermatol & Venereol, Lund, Sweden
[3] Malmo Univ, Dept Biomed Lab Sci, Malmo, Sweden
来源
SHOCK | 2008年 / 30卷 / 06期
关键词
Sepsis; GAG; syndecan-1; prognosis; cardiac failure; circulation; glycocalyx; antibacterial activity;
D O I
10.1097/SHK.0b013e3181777da3
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Glycosaminoglycans (GAGs) are structurally heterogeneous negatively charged polysaccharides. Endothelial GAGs, also known as glycocalyx, are involved in capillary permeability. In rat venules stimulated with proinflammatory substances ex vivo, the GAG-containing proteoglycan, syndecan-1, is shed from the endothelium. We wanted to investigate if we could trace the same response during septic shock as reflected in the circulating GAG levels. Arterial plasma samples were collected from 18 consecutive septic shock patients admitted to our intensive care unit. Plasma GAGs were measured with an Alcian blue slot binding assay, and syndecan-1 levels were measured with enzyme-linked immunosorbent assay. Effects of GAGs on the antibacterial activity of plasma were assessed by a radial diffusion assay. The median plasma GAG level was significantly higher in the septic shock patients than in matched controls (median [interquartile range], 2.7 mu g/mL [1.9 - 4.8 mu g/mL] vs. 1.8 mu g/mL [1.7 - 2.0 mu g/mL]). Furthermore, the GAG levels were significantly higher in nonsurvivors (4.6 mu g/mL [3.1 - 8.8 mu g/mL], n = 8) than survivors (1.8 mu g/mL [1.6 - 2.6 mu g/mL], n = 10). The syndecan-1 levels were also increased in the patients compared with controls (246 ng/mL [180 - 496 ng/mL] vs. 26 ng/mL [23 - 31 ng/mL]) and correlated to the cardiovascular Sequential Organ Failure Assessment (SOFA) score. The GAGs inhibited the endogenous antibacterial activity of plasma as well as isolated antimicrobial peptides. The concentrations required were in the same range as the GAG levels measured in the patients. These results show that the GAG levels are increased in septic shock patients, possibly reflecting peripheral endothelial cell damage. We also found that GAGs in relevant concentrations neutralize antimicrobial peptides in plasma.
引用
收藏
页码:623 / 627
页数:5
相关论文
共 27 条
[1]
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome [J].
Aird, WC .
BLOOD, 2003, 101 (10) :3765-3777
[2]
Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids [J].
Baranska-Rybak, W ;
Sonesson, A ;
Nowicki, R ;
Schmidtchen, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (02) :260-265
[3]
Heparanase pretreatment attenuates endotoxin-induced acute lung injury in rats [J].
Bashenko, Yulia ;
Ilan, Neta ;
Krausz, Michael M. ;
Vlodavsky, Israel ;
Hirsh, Mark I. .
SHOCK, 2007, 28 (02) :207-212
[4]
Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: Clinical results of a pilot study [J].
Bengsch, S ;
Boos, KS ;
Nagel, D ;
Seidel, D ;
Inthorn, D .
SHOCK, 2005, 23 (06) :494-500
[5]
Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis [J].
Björnsson, S .
ANALYTICAL BIOCHEMISTRY, 1998, 256 (02) :229-237
[6]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]
Syndecans in inflammation [J].
Götte, M .
FASEB JOURNAL, 2003, 17 (06) :575-591
[8]
Götte M, 2002, INVEST OPHTH VIS SCI, V43, P1135
[9]
Syndecan 1 shedding contributes to Pseudomonas aeruginosa sepsis [J].
Haynes, A ;
Ruda, F ;
Oliver, J ;
Hamood, AN ;
Griswold, JA ;
Park, PW ;
Rumbaugh, KP .
INFECTION AND IMMUNITY, 2005, 73 (12) :7914-7921
[10]
KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303